Patents by Inventor Jason R. Abbott

Jason R. Abbott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250122160
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: April 26, 2024
    Publication date: April 17, 2025
    Inventors: Philip R. Kym, Jennifer M. Frost, Christos Economou, Andrew Bogdan, Stacy Fosu, Zhaoming Xiong, Spencer O. Scholz, Eric Allan Voight, Elliot P. Farney, Mark A. Matulenko, Matthew J. O'Connor, Christina Baumgartner, Qingwei Zhang, Reza Shiroodi, Jason R. Abbott, Geoff T. Halvorsen
  • Publication number: 20230019236
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: June 16, 2022
    Publication date: January 19, 2023
    Inventors: Elliot P. Farney, Reza Shiroodi, Zhaoming Xiong, Qingwei Zhang, Matthew J. O'Connor, Geoff T. Halvorsen, Hongyu Zhao, Christina Baumgartner, Jennifer M. Frost, Philip R. Kym, Jason R. Abbott, Andrew Bogdan, Christos Economou, Xueqing Wang
  • Patent number: 11318137
    Abstract: The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 3, 2022
    Assignee: Vanderbilt University
    Inventors: Alex G. Waterson, Jason R. Abbott, J. Phillip Kennedy, Stephen W. Fesik, Qi Sun, Jason Phan, Michael C. Burns, Pratiq Patel
  • Publication number: 20200253974
    Abstract: The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.
    Type: Application
    Filed: May 17, 2017
    Publication date: August 13, 2020
    Inventors: Alex G. Waterson, Jason R. Abbott, J. Phillip Kennedy, Stephen W. Fesik, Qi Sun, Jason Phan, Michael C. Burns, Pratiq Patel
  • Patent number: 10501421
    Abstract: Benzimidazole compounds that increase the rate of SOS-mediated nucleotide exchange on Ras by binding to a functionally relevant, chemically tractable pocket on the SOS protein, as part of the Ras:SOS:Ras complex.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 10, 2019
    Assignee: Vanderbilt University
    Inventors: Steve Fesik, Alex Waterson, Michael Burns, Qi Sun, Jason Phan, James M. Salovich, Jason R. Abbott, Andrew Little